Related references
Note: Only part of the references are listed.BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
Brandon S. Sheffield et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Loss of expression of BAP1 predicts longer survival in mesothelioma
Mahtab Farzin et al.
PATHOLOGY (2015)
Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
Guangwu Guo et al.
CANCER RESEARCH (2015)
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Francine Baumann et al.
CARCINOGENESIS (2015)
Malignant Peritoneal Mesothelioma: Prognostic Factors and Oncologic Outcome Analysis
Deepa Magge et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Diagnostic Usefulness of p16/CDKN2A FISH in Distinguishing Between Sarcomatoid Mesothelioma and Fibrous Pleuritis
Di Wu et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2013)
p16 Deletion in Sarcomatoid Tumors of the Lung and Pleura
Naobumi Tochigi et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
Marjorie G. Zauderer et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma
H. Richard Alexander et al.
SURGERY (2013)
A Novel Tumor-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of A Multi-Institutional Database
Tristan D. Yan et al.
CANCER (2011)
A new standard of care for the management of peritoneal surface malignancy
F. Mohamed et al.
Current Oncology (2011)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew Bott et al.
NATURE GENETICS (2011)
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
Catherine T-S Chung et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
Alyssa M. Krasinskas et al.
MODERN PATHOLOGY (2010)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Malignant Pleural Mesothelioma
Anne S. Tsao et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Functional inactivation of NF2/merlin in human mesothelioma
Claudio Thurneysen et al.
LUNG CANCER (2009)
Malignant peritoneal mesothelioma
Stine Munkholm-Larsen et al.
WORLD JOURNAL OF GASTROINTESTINAL SURGERY (2009)
A conditional mouse model for malignant mesothelioma
Johan Jongsma et al.
CANCER CELL (2008)
Peritoneal Mesothelioma
Mary E. Hesdorffer et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2008)
Consensus statement on peritoneal mesothelioma
Marcello Deraco et al.
JOURNAL OF SURGICAL ONCOLOGY (2008)
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
Simion Chiosea et al.
MODERN PATHOLOGY (2008)
Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma
Naruyuki Kobayashi et al.
LUNG CANCER (2008)
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
Sanja Dacic et al.
VIRCHOWS ARCHIV (2008)
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
T. D. Yan et al.
ANNALS OF ONCOLOGY (2007)
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
A. C. Borczuk et al.
ONCOGENE (2007)
Global gene expression profiling of pleural mesotheliomas:: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction
F López-Ríos et al.
CANCER RESEARCH (2006)
Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion
M Deraco et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression
GH Xiao et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
JK Trupiano et al.
MODERN PATHOLOGY (2004)
Mesothelioma trends in the United States: An update based on surveillance, epidemiology, and end results program data for 1973 through 2003
B Price et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy
AL Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours
J Fleury-Feith et al.
ONCOGENE (2003)
Share Paper
